CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
$6.07-5.31%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
Research Workspace
Put CTSO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain Nasdaq listing compliance: Compliance deadline 2026-09-28 vs current date 2026-09-14.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 127% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 69% in its worst 12-month stretch.
View RiskCTSO's growth in key clinical applications must continue to justify its current valuation. Revenue grew modestly in Q2 2026, with a slight beat against expectations. It trades at 10.7× price-to-sales, compared to a peer median of 2.9×. The market is pricing in more growth than forecast, indicating expectations look full. A specific risk is the potential for guidance cuts, with a near 48% miss probability for the next quarter. Peer multiples imply a price about 143% below where it trades (it looks expensive on this basis). This read is provisional; the thesis is on watch.
Trailing returns as of 2026-09-14. CTSO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering CTSO (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CTSO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CTSO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put CTSO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
CEO's investment signals confidence in company prospects.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Drive growth in key clinical applications
Revenue beat indicates growth in key clinical applications.
